Skip to content

News

Asgard Therapeutics raises EUR 6M in Seed Financing to exploit direct in vivo reprogramming

November 9, 2021
• Round co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden• Company developing in vivo immune cell reprogramming technology to reinstate anti-cancer immunity• Funds will be used to further
Read More

Asgard Therapeutics highlighted as finalist of the 2021 Merck EU Advance Biotech Grants Program

May 17, 2021
Asgard Therapeutics was shortlisted as a finalist of the 2021 Merck EU Advance Biotech Grants Program. This program aims to support emerging biotech companies pushing innovative drugs to the market
Read More

Asgard Therapeutics awarded with Sweden’s SWElife Innovation Grant

April 1, 2021
Asgard Therapeutics was awarded with Sweden’s SWElife innovation grant to support the project “Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC” in collaboration
Read More

Fábio Rosa highlighted as one of the young 34 promising Scanian personalities of 2020

December 18, 2020
Rapidus and PwC ​​highlighted Fábio Rosa as one of 34 young promising Scanian personalities and driven entrepreneurs of this year.
Read More

Asgard Therapeutics highlighted at the Medicon Valley Alliance/ Øresundsinstituttet report

December 18, 2020
In a new survey published by Øresund Institute and Medicon Valley Alliance, Asgard Therapeutics was highlighted as one of 426 life science companies in Skåne.  https://www.oresundsinstituttet.org/life-science-skane/?utm_campaign=unspecified&utm_content=unspecified&utm_medium=email&utm_source=apsis-anp-3
Read More

Filipe Pereira awarded with Mats Paulsson Grant 2020

December 11, 2020
Mats Paulsson Foundations awarded Filipe Pereira, co-founder of Asgard Therapeutics, with a Mats Paulsson Grant 2020. Since 2019, the foundation has focused on grants for academic research projects that in
Read More

Filipe Pereira awarded with the KiiLN Postdoctoral Entrepreneurship Award

December 10, 2020
The KiiLN- Keystone for Incubating Innovation in Life Sciences Network team and Icahn School of Medicine at Mount Sinai awarded Filipe Pereira, co-founder of Asgard Therapeutics, the KiiLN Postdoctoral Entrepreneurship Award. This award
Read More

Asgard Therapeutics becomes a SmiLe member

November 17, 2020
Asgard Therapeutics AB has been admitted to SmiLe Incubator as the next step to move forward on the pre-clinical studies of their lead program TrojanDC. https://news.smileincubator.com/posts/pressreleases/immunotherapy-company-asgard-therapeutics-is
Read More

Asgard featured on the Pharma Industry report about ATMPs in Sweden

September 24, 2020
Advanced Therapies Medical Products (ATMPs) are considered the “drugs of the future”. These are based on gene, cell and tissue products. Sweden has the ambitious goal of becoming a leader
Read More

Filipe Pereira, Cristiana Pires and Fábio Rosa, co-founders of Asgard Therapeutics, awarded with the Lund University and Sparbanken Skåne’s prize for future innovations

September 23, 2020
Together with Sparbanken Skåne, in collaboration with the Sparbanksstiftelsen Finn, Lund University awarded Filipe Pereira, Cristiana Pires and Fábio Rosa the Lund University and Sparbanken Skåne’s prize for future innovations.
Read More

Filipe Pereira, co-founder of Asgard Therapeutics, awarded with a BII PreSeed grant

April 1, 2020
The BioInnovation Institute (BII) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with DKK 3.5M to advance pre-clinical development of dendritic cell reprogramming and define its regulatory roadmap towards the clinic.
Read More

Asgard Therapeutics awarded Vinnova’s Innovative Startup Step 2

March 31, 2020
Swedish start-up company Asgard Therapeutics has been awarded the second step of Vinnova’s Innovative Startup program in order to further develop a new cancer immunotherapy based on dendritic cell reprogramming.
Read More